About ProteoNic
Our mission
To enable the production of complex therapeutic proteins and other biologics by offering premium technology to our clients for improved productivity and cost-effectiveness
Our vision
ProteoNic’s technology widely applied by developers and contract manufacturers to the benefit of patients everywhere
ProteoNic is a vector technology company with strong commercial validation. The company licenses its technology platforms to clients performing development or manufacturing of biologics and viral vectors.
The company benefits from being headquartered in Leiden, one of the largest life science hubs in Europe, and has an office in Boston for business development in the US.
ProteoNic offers key technologies for bioproduction and viral vector manufacturing, aimed at improving productivity and cost-effectiveness of development and production of biopharmaceuticals, other biologics as well as cell and gene therapies.
ProteoNic offers premium vector technology that substantially boosts production levels of therapeutic proteins, other biologics and viral vector titers. Cost savings are immediate and sizeable, freeing up production capacity and enabling commercially viable production of difficult to express proteins.
CHO-2G UNic® for mammalian cells was launched in 2017 and has seen extensive commercial validation and market uptake based on non-exclusive licensing to clients.
ProteoNic also offers other technologies for of bioproduction which impact productivity and product quality. Read more
ProteoNic’s patented technology does not require modifications to existing production systems or work flows and is compatible with all production cell lines and expression systems used in the industry. Read more
Company culture
We are entrepreneurial and science-driven specialists in the production of biologics. We love providing solutions to new challenges. Nothing is more satisfying than helping our clients turn a promising, but ultimately unprofitable, protein into a commercially viable product to allow them to offer new and exciting treatment options or develop innovative new products.
Meet the Management Team
Frank Pieper
Chief Executive Officer
Frank has served as ProteoNic’s CEO since 2011 and brings over 30 years of experience in biotechnology and life sciences. Following his training in molecular biology, he has held various senior management positions in the biotech industry across a broad range of corporate development activities. These include R&D, product development, strategic planning and licensing, operations, manufacturing, business development and intellectual property management. He was involved in various financing rounds and a Euronext IPO.
Maurice van der Heijden, PhD
Director R&D
Maurice van der Heijden has extensive expertise in molecular and cell biology studies. After obtaining a PhD in molecular virology from Leiden University, he held postdoctoral positions at Leiden and Utrecht Universities. He brings his experience in antibody discovery from Janssen Pharmaceutical Companies to his position at ProteoNic where he oversees the scientific development program and technical customer support.
Guido Kwikkers
Chief Financial Officer
Guido has a degree in business administration and a well-rounded background in the financial, IT and legal disciplines from various international assignments. He brings his experience leading corporate restructuring at a large multinational company and setting up a new company to his position as CFO at ProteoNic.
Frank Pieper
Guido Kwikkers
Maurice van der Heijden, PhD
Chief Executive Officer
Chief Financial Officer
Director R&D
Frank has served as ProteoNic’s CEO since 2011 and brings over 30 years of experience in biotechnology and life sciences. Following his training in molecular biology, he has held various senior management positions in the biotech industry across a broad range of corporate development activities. These include R&D, product development, strategic planning and licensing, operations, manufacturing, business development and intellectual property management. He was involved in various financing rounds and a Euronext IPO.
Guido has a degree in business administration and a well-rounded background in the financial, IT and legal disciplines from various international assignments. He brings his experience leading corporate restructuring at a large multinational company and setting up a new company to his position as CFO at ProteoNic.
Maurice van der Heijden has extensive expertise in molecular and cell biology studies. After obtaining a PhD in molecular virology from Leiden University, he held postdoctoral positions at Leiden and Utrecht Universities. He brings his experience in antibody discovery from Janssen Pharmaceutical Companies to his position at ProteoNic where he oversees the scientific development program and technical customer support.
Mark Posno, PhD
Vice President Business Development
Mark has more than 20 years of experience in global business development in the pharmaceutical and biotechnology industries. He trained as a molecular biologist and has extensive experience in translating protein production technologies into business propositions. Mark has been involved in various biotechnology companies and research institutes in the US and Europe. Located in the USA, Mark is responsible for global commercial development and strategic partnerships.
Jonathan Frampton, PhD
Director Business Development
Working at ProteoNic
Are you looking for a new challenge?
ProteoNic is a dynamic group of scientists and entrepreneurs who are dedicated to helping its licensees by increasing productivity and cost-effectiveness of pharmaceutical protein production. Our broadly applicable solutions are constantly evolving and can be tailored to new clients or products, so there’s always a new challenge to tackle and a satisfying solution to be found.
Help us make a difference!
Working at ProteoNic
Please take a look at our careers page for open positions: Careers